NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...
2don MSN
Cracking the code of a hidden cancer receptor: How scientists found the first true Frizzled blocker
Researchers at Karolinska Institutet have identified small molecules capable of influencing a hard-to-target receptor family ...
Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on ...
An AI-driven computational toolkit, Gcoupler, integrates ligand design, statistical modeling, and graph neural networks to predict endogenous metabolites that allosterically modulate the GPCR–Gα ...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN) ...
(RTTNews) - Axsome Therapeutics Inc. (AXSM) has secured exclusive global rights to AZD7325, a novel oral GABAA receptor a2,3 subtype-selective positive allosteric modulator, from AstraZeneca. The ...
WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...
Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback